aEquipe émergente Médicaments Anti-infectieux et Barrière Hématoencéphalique, Laboratoire de Pharmacie Galénique et Biopharmacie, Faculté de Médecine et de Pharmacie, 34 rue du Jardin des Plantes, BP199, 86005 Poitiers Cedex, FrancebLaboratoire de Biologie des Interactions Cellulaires, CNRS UMR 6558, Faculté des Sciences, 40 avenue du Recteur Pineau, 86022 Poitiers Cedex, FrancecLaboratoire du Développement Cortical, CNRS UMR 6558, Faculté des Sciences, 40 avenue du Recteur Pineau, 86022 Poitiers Cedex, France
Checking for direct PDF access through Ovid
The aim of this work was to study in rats the nasal route for the brain delivery of the vasoactive intestinal peptide (VIP) neuropeptide. After evaluating VIP stability in solutions obtained from nasal washes, the effect of formulation parameters (pH 4–9, 0–1% (w/v) lauroylcarnitine (LC), hypo- or isoosmolality) on the brain uptake of intranasally administered VIP (10−8 M)/Symbol-VIP (300,000 cpm/ml) was studied, using an in situ perfusion technique. Brain radioactivity distribution was assessed by quantitative autoradiographic analysis. Results were compared to intravenously administered VIP. With a hypotonic formulation at pH 4 containing 0.1% LC and 1% bovine serum albumin, VIP stability was satisfactory and loss by adsorption was minimal. Using this formulation, around 0.11% of initial radioactivity was found in the brain after 30 min perfusion and was located in the olfactory bulbs, the midbrain and the cerebellum. HPLC analysis of brain and blood extracts demonstrated the presence of intact VIP in brain and its complete degradation in the blood compartment. By intravenous administration, no intact VIP was found either in brain or in blood. In conclusion, intact VIP could be delivered successfully to the brain using the intranasal route for administration.